Literature DB >> 8938519

Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor.

B A Pierson1, A F Europa, W S Hu, J S Miller.   

Abstract

Large-scale ex vivo expansion of human natural killer (NK) cells for adoptive immunotherapy requires assurance of good manufacturing practices. However, maximal expansion of NK is also desired to facilitate clinical trials with large numbers of IL-2-activated NK (ANK). A closed-system stirred-tank bioreactor is amenable to computer control of culture variables, thereby reducing the risk of contamination. We demonstrate that NK cultured in 250-ml spinner flasks expand 2.5-fold more than NK cultured in stationary tissue culture wells. We further show that during 33 days of culture, it is feasible to control the pH between 7.0 and 7.2 and the dissolved oxygen concentration at 40% of air saturation via direct on-line computer control in a 750-ml stirred-tank bioreactor. On-line measurement of optical density by a laser turbidity sensor, as a measure of cell concentration, correlated well with actual cell count data. NK expansion in the 750-ml bioreactor was 7-fold greater than in stationary tissue culture controls and 3-fold greater than in spinner flask controls. Consumption rates of glucose and oxygen and the production rate of lactate were measured and will be used to develop a nutrient feeding strategy to convert the batch reactor experiment into closed-system fed-batch or continuous flow modes. Computer-controlled stirred-tank bioreactors may facilitate clinical trials with high-purity ANK populations for adoptive immunotherapy.

Entities:  

Mesh:

Year:  1996        PMID: 8938519     DOI: 10.1089/scd.1.1996.5.475

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  6 in total

1.  Expansion of mouse sertoli cells on microcarriers.

Authors:  B Shi; S Zhang; Y Wang; Y Zhuang; J Chu; S Zhang; X Shi; J Bi; M Guo
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

2.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

Authors:  Melissa A Geller; Sarah Cooley; Patricia L Judson; Rahel Ghebre; Linda F Carson; Peter A Argenta; Amy L Jonson; Angela Panoskaltsis-Mortari; Julie Curtsinger; David McKenna; Kathryn Dusenbery; Robin Bliss; Levi S Downs; Jeffrey S Miller
Journal:  Cytotherapy       Date:  2010-09-20       Impact factor: 5.414

3.  Design, characterization and application of a minibioreactor for the culture of human hematopoietic cells under controlled conditions.

Authors:  A De León; H Mayani; O T Ramírez
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

Review 4.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Authors:  Markus Granzin; Juliane Wagner; Ulrike Köhl; Adelheid Cerwenka; Volker Huppert; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

Review 5.  Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.

Authors:  Erica L Heipertz; Evan R Zynda; Tor Espen Stav-Noraas; Andrew D Hungler; Shayne E Boucher; Navjot Kaur; Mohan C Vemuri
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

Review 6.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.